PHENETH-LAD

PHENETH-LAD, or PHENETHY-LAD, also known as 6-(β-phenethyl)-6-nor-LSD, is a drug of the lysergamide family related to lysergic acid diethylamide (LSD).^{[1][2][3][4][5]} It is the derivative of LSD in which the methyl group at the 6 position has been replaced with a phenylethyl moiety.^[1][2][3]

Other namesPHENETHLAD; PHENETHY-LAD; PHENETHYLAD; 6-(β-Phenethyl)-6-nor-LSD; N-Phenethyl-nor-LSD; N,N-Diethyl-6-phenethyl-6-norlysergamide; N,N-Diethyl-6-(2-phenylethyl)-9,10-didehydroergoline-8β-carboxamide

ATC code

• None

PubChem CID

• 44457779

ChemSpider

• 23120272

Quick facts Clinical data, Other names ...

PHENETH-LAD

Clinical data
Other names	PHENETHLAD; PHENETHY-LAD; PHENETHYLAD; 6-(β-Phenethyl)-6-nor-LSD; N-Phenethyl-nor-LSD; N,N-Diethyl-6-phenethyl-6-norlysergamide; N,N-Diethyl-6-(2-phenylethyl)-9,10-didehydroergoline-8β-carboxamide
ATC code	None
Identifiers
IUPAC name (6aR,9R)-N,N-diethyl-7-(2-phenylethyl)-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
PubChem CID	44457779
ChemSpider	23120272
ChEMBL	ChEMBL23046
Chemical and physical data
Formula	C27H31N3O
Molar mass	413.565 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)CCC5=CC=CC=C5
InChI InChI=1S/C27H31N3O/c1-3-29(4-2)27(31)21-15-23-22-11-8-12-24-26(22)20(17-28-24)16-25(23)30(18-21)14-13-19-9-6-5-7-10-19/h5-12,15,17,21,25,28H,3-4,13-14,16,18H2,1-2H3/t21-,25-/m1/s1 Key:YCWXYUACPTXUEC-PXDATVDWSA-N

Close

The drug failed to substitute for LSD in rodent drug discrimination tests, with a maximum of 25 or 50% LSD-appropriate responding at the highest assessed dose.^[1][4][5] Unlike other 6-substituted lysergamides, PHENETH-LAD was not assessed at the serotonin receptors.^[1][5] According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), PHENETH-LAD produced no effects in humans at a dose of 500 μg.^[3] He has specified the potentially active dose as being >350 μg and its hallucinogenic potency being less than 30% of that of LSD.^[2][6]

PHENETH-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University in 1985.^[4] Its effects in humans were first described by Shulgin by 1994.^[6][3]